ArticleScientific reports2025
Association between subretinal fluid duration in central serous chorioretinopathy and chorioretinal structure in unaffected fellow eyes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the association between the duration of subretinal fluid (SRF) persistence in affected eyes and baseline chorioretinal structure in unaffected fellow eyes among patients with unilaterally naïve central serous chorioretinopathy (CSC). This retrospective case series comprised 25 healthy control patients and 46 patients with unilaterally naïve CSC, defined as first-episode and untreated within 1 month from symptom onset, who were categorized into prolonged (> 3 months) and nonprolonged (≤ 3 months) groups according to SRF duration in affected eyes from the first visit. Central retinal thickness, outer nuclear layer thickness, central choroidal thickness (CCT), luminal area (LA), stromal area (SA), total choroidal area (TCA), and choroidal vascularity index (CVI) were measured in unaffected fellow eyes at the first visit, and the duration of SRF persistence in affected eyes was recorded. As a result, CCT, SA and TCA were significantly greater, and CVI was significantly lower in the unaffected fellow eyes compared to the healthy control eyes (all p < 0.05). The optimal model for predicting SRF persistence > 3 months in affected eyes involved CVI (p = 0.015) in fellow eyes. Baseline choroidal thickening, mainly in the choroidal stroma of unaffected fellow eyes, was shown to correlate with SRF persistence in the affected eyes in unilateral naïve CSC. This information may be valuable for the identifying cases with a heightened risk of prolonged SRF persistence and for the timely initiation of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.